SCHEMBL25375145

SCHEMBL25375145

Cc1ccccc1/C=N\CC(C)C

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 5/20 0.45
RAB9A P51151 5/20 0.45
KDM4E B2RXH2 5/20 0.44
MAPT P10636 4/20 0.44
ALDH1A1 P00352 3/20 0.42
TSHR P16473 1/20 0.42
SMN1; SMN2 Q16637 3/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
LMNA P02545 2/20 0.38
MAPK1 P28482 1/20 0.38
HPGD P15428 1/20 0.38
HTT P42858 1/20 0.38
CA12 O43570 3/20 0.37
CA2 P00918 3/20 0.37
CNR2 P34972 1/20 0.37
CA9 Q16790 2/20 0.35
KMT2A Q03164 2/20 0.35
GAA P10253 1/20 0.35
MEN1 O00255 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25379185 0.92 ALDH1A1 (0.58) NPC1RAB9AKDM4EMAPTALDH1A1
SCHEMBL25650172 0.87 KDM4E (0.55) NPC1RAB9AKDM4EMAPTALDH1A1
SCHEMBL25377554 0.84 ALDH1A1 (0.38) NPC1RAB9AKDM4EMAPTALDH1A1
SCHEMBL25377557 0.84 ALDH1A1 (0.38) NPC1RAB9AKDM4EMAPTALDH1A1
SCHEMBL25377555 0.84 ALDH1A1 (0.38) NPC1RAB9AKDM4EMAPTALDH1A1
SCHEMBL21957542 0.81 ALDH1A1 (0.36) NPC1RAB9AKDM4EMAPTALDH1A1
SCHEMBL21957543 0.81 ALDH1A1 (0.36) NPC1RAB9AKDM4EMAPTALDH1A1
SCHEMBL15833494 0.80 KDM4E (0.38) NPC1RAB9AKDM4EMAPTALDH1A1
SCHEMBL11089874 0.79 CA12 (0.57) NPC1RAB9AKDM4EMAPTALDH1A1
SCHEMBL11089873 0.79 CA12 (0.57) NPC1RAB9AKDM4EMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250136594-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2025-05-01 US disclosed
EP-4469438-A1 COMPOUNDS AND METHODS OF USE Tango Therapeutics, Inc. (US) 2024-12-04 EP disclosed
WO-2023146987-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. (US) 2023-08-03 WO disclosed
WO-2023146987-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. (US) 2023-08-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250136594-A1 COMPOUNDS AND METHODS OF USE CNKSR1, UGT1A1, REV1 NPC1 1403/4885RAB9A 190/4885KDM4E 1639/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.